300244 迪安诊断
2025/12 -
人民幣(K¥)

变动
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入10,096,032-17.22%13,408,32020,282,46913,082,61310,649,162
减:营业总成本9,550,981-16.25%12,243,28216,603,82111,084,4098,862,648
    其中:营业成本7,222,146-17.74%9,213,38312,745,8118,076,9496,578,706
               财务费用156,601-20.92%220,608298,236217,479195,875
               资产减值损失(96,289)-76.02%(16,738)(624,025)(272,189)(475,247)
公允价值变动收益3,528-127.78%(727)(56,236)83,354(2,586)
投资收益26,194-32.34%(17,596)48,78755,33873,148
    其中:对联营企业和合营企业的投资收益18,04055.73%(6,722)26,76339,78520,783
营业利润281,315-1,004.11%842,1832,822,6091,837,9351,320,311
利润总额256,190-594.32%798,3262,543,5621,790,9971,317,395
减:所得税费用110,584-5.81%216,735681,092307,396247,461
净利润145,606-186.04%581,5911,862,4701,483,6011,069,934
减:非控股权益101,554-45.99%274,130428,279320,717267,002
股东净利润44,053-112.33%307,4611,434,1911,162,884802,933

市场价值指针
每股收益 (元) *0.072-112.45%0.4922.3021.8741.294
每股派息 (元) *0.350-61.11%0.0600.2000.1350.130
每股净资产 (元) *10.308-1.86%12.06911.8819.4167.572
审计意见 #标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容